PTEN mutations and evolving concepts in endometrial neoplasia

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 1, 2002, Pages 59-65

  Latta, Eleanor ^a   Chapman, William B ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; DISEASE COURSE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENE MUTATION; GENE REPLICATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSATELLITE INSTABILITY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ENDOMETRIAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; MICROSATELLITE REPEATS; PHOSPHORIC MONOESTER HYDROLASES; PRECANCEROUS CONDITIONS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0036183633     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200202000-00010     Document Type: Review

References (77)

1. Two pathogenetic types of endometrial carcinoma
2. The molecular biology of endometrial tumorigenesis: Does it have a message?
3. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis
4. The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma
5. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
6. The behavior of endometrial hyperplasia: A long-term study of 'untreated' hyperplasia in 170 patients
7. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma
8. A multicentric European study testing the reproducibility of the World Health Organization classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens
9. Histopathology of genetically defined endometrial precancers
10. Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos?
11. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis
12. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer
13. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry
14. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with microsatellite instability
15. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer
16. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone
17. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long term retrospective study from northern Norway
18. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias
19. Atypical endometrial hyperplasia shares genomic abnormalities with endometrioid carcinoma by comparative genomic hybridization
20. Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization
21. Intratumoral genetic heterogeneity and progression of endometrioid type endometrial adenocarcinomas
22. PTEN: A tumour suppressor that functions as a phospholipid phosphatase
23. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
24. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis
25. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
26. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
27. Will the real Cowden syndrome please stand up: Revised diagnostic criteria
28. Somatic mutations of PTEN in glioblastoma multiforme
29. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
30. Identification of PTEN mutations in metastatic meranoma specimens
31. PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases
32. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies
33. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
34. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma
35. PTEN, a protean tumor suppressor
36. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies
37. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
38. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma
39. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers
40. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors
41. Allelic imbalance and mutations of the PTEN gene in ovarian cancer
42. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas
43. Common genetic changes between endometriosis and ovarian cancer
44. Changes in endometrial PTEN expression throughout the human menstrual cycle
45. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α
46. Molecular identification of latent precancers in histologically normal endometrium
47. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma
48. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias
49. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics
50. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers
51. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia
52. 1 growth arrest in glioma cells
53. 1 cell cycle arrest in human glioblastoma cells
54. 1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells
55. Tumor suppressor PTEN inhibits nuclear accumulation of β-catenin and T-cell/lymphoid enhancer factor 1-mediated transcriptional activation
56. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways
57. The multiple roles of PTEN in tumor suppression
58. Microsatellite instability in endometrial carcinoma
59. Genetic instability of microsatellites in endometrial carcinoma
60. Microsatellite instability in sporadic endometrial carcinoma
61. Microsatellite instability in endometrial cancer: Relation to histological subtypes
62. Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma
63. Causes and consequences of microsatellite instability in endometrial carcinoma
64. Microsatellite instability and somatic mutations in endometrial carcinomas
65. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma
66. Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues
67. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer
68. Methylation of hMLH1 in a population-based series of endometrial carcinomas
69. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis
70. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers
71. Clinical significance of microsatellite instability in endometrial carcinoma
72. Favorable survival associated with microsatellite instability in endometrioid endometrioid cancers
73. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability
74. Molecular pathology of endometrial hyperplasia and carcinoma
75. β-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis
76. Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of lκB-α that can be inhibited by the tumor suppressor PTEN
77. HER-2/neu amplification and overexpression in endometrial carcinoma